Center-Authored Papers

Filters: Author is Gamis, Alan  [Clear All Filters]
2010
Radhi M, Meshinchi S, Gamis A.  2010.  Prognostic factors in pediatric acute myeloid leukemia.. Current hematologic malignancy reports. 5(4):200-6. Abstract
2012
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al..  2012.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.. Blood. 119(16):3705-11. Abstract
Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ et al..  2012.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group.. Cancer. 118(3):761-769. Abstract
Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL et al..  2012.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS.  2012.  Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant Recipients.. Journal of clinical pharmacology. Abstract
2013
Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC et al..  2013.  Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.. British journal of haematology. 162(2):250-62. Abstract
McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS.  2013.  Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.. Journal of clinical pharmacology. 53(3):264-75. Abstract
Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J et al..  2013.  Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(6):1620-1627. Abstract
McCune JS, Bemer MJ, Barrett J, Baker KS, Gamis A, Holford N.  2013.  Busulfan in infants to adult hematopoietic cell transplant recipients: A population pharmacokinetic model for initial and Bayesian dose personalization.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, Meshinchi S, Alonzo TA, Gamis A, Aplenc R.  2013.  Gene Expression Profiling to Predict Viridans Group Streptococcal and Invasive Fungal Infection in Pediatric Acute Myeloid Leukemia: A Brief Report from the Children's Oncology Group.. Acta haematologica. 131(3):167-169.
Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ, Meshinchi S, Woods WG, Perentesis J et al..  2013.  Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: A Report from the Children's Oncology Group.. Cancer. Abstract
2015
Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A et al..  2015.  Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Laszlo G, Alonzo TA, Gudgeon C, Harrington K, Gerbing R, Wang Y-C, Ries R, Raimondi S, Hirsch BA, Gamis A et al..  2015.  Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(14):3187-95. Abstract
2016
Schultz KAP, Chen L, Kunin-Batson A, Chen Z, Woods WG, Gamis A, Kawashima T, Oeffinger KC, Nicholson SH, Neglia JP.  2016.  Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group.. Journal of pediatric hematology/oncology. Abstract